In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, according to a study published in JAMA Pediatrics.
Getting Started is Easy and Yes It's FREE
What is The Ecosystem?
The Token Revolution.
The Next Bitcoin Moment.
